Cargando…

Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography ((68)Ga-DOTATATE and (18)F-fluorodeoxyglucose) molecular imaging and disease stabilization following (177)Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy

Debate exists on the disease biology and course of primary large cell neuroendocrine carcinoma (LCNEC) of larynx, being classified as a variant of atypical carcinoid by the World Health Organisation-2005 classification, while literature of its aggressive behavior indicating poorly differentiated neu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jadhav, Sonali, Basu, Sandip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945362/ https://www.ncbi.nlm.nih.gov/pubmed/31933564 http://dx.doi.org/10.4103/wjnm.WJNM_76_18

Ejemplares similares

Prevalence of hitherto unknown brain meningioma detected on (68)Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of (177)Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
por: Parghane, Rahul V., et al.
Publicado: (2019)

Radiomics-Based Texture Analysis of (68)Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With Neuroendocrine Cancers Treated With (177)Lu-DOTATATE
por: Atkinson, Charlotte, et al.
Publicado: (2021)

(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites
por: Thapa, Pradeep, et al.
Publicado: (2017)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

(177)Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
por: Kumar Jaiswal, Sanjeet, et al.
Publicado: (2020)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

Modeling Early Radiation DNA Damage Occurring During (177)Lu-DOTATATE Radionuclide Therapy
por: Tamborino, Giulia, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE for Metastatic Neuroendocrine Tumor Occurring in Association with Multiple Endocrine Neoplasia Type 1 and Cushing's Syndrome
por: Naik, Chinna, et al.
Publicado: (2017)

Diagnosis of Men-I Syndrome on (68)Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE
por: kumar Gupta, Santosh, et al.
Publicado: (2012)

Grade 3 metastatic neuroendocrine neoplasms of two unusual primary sites with contrasting differentiation characteristics: Dual tracer positron emission tomography and computed tomography imaging ((18)F-fluorodeoxyglucose and (68)Ga-DOTATATE) correlates and their treatment implications
por: Loharkar, Sarvesh, et al.
Publicado: (2020)

Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
por: Levart, D., et al.
Publicado: (2019)

SPECT image segmentation for estimation of tumour volume and activity concentration in (177)Lu-DOTATATE radionuclide therapy
por: Gustafsson, Johan, et al.
Publicado: (2017)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

(90)Y/(177)Lu-DOTATATE therapy: survival of the fittest?
por: Brans, Boudewijn, et al.
Publicado: (2011)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

Tissue dose estimation after extravasation of (177)Lu-DOTATATE
por: Tylski, Perrine, et al.
Publicado: (2021)

Efficacy of (177)Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma
por: Zahid, Anza, et al.
Publicado: (2021)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

Comparison of commercial dosimetric software platforms in patients treated with (177)Lu‐DOTATATE for peptide receptor radionuclide therapy
por: Mora‐Ramirez, Erick, et al.
Publicado: (2020)

Predicting [(177)Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [(68)Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
por: Siebinga, Hinke, et al.
Publicado: (2023)

(68)Ga-DOTATATE-positron emission tomography imaging in spinal meningioma
por: Slotty, Philipp Jörg, et al.
Publicado: (2014)

Spinal molecular imaging by (68) Ga-DOTATATE-positron emission tomography
por: Sandu, Nora, et al.
Publicado: (2014)

Clinical efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A “not-so-promising” result compared to GEP-NETs
por: Basu, Sandip, et al.
Publicado: (2020)

(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Borderline Low and Discordant Renal Parameters: Treatment Feasibility Assessment by Sequential Estimation of Triple Parameters and Filtration Fraction
por: Naik, Chinna, et al.
Publicado: (2018)

Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with (177)Lu-DOTATATE
por: Vyakaranam, Achyut Ram, et al.
Publicado: (2019)

Repurposed Effect of (177)Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma
por: Elajami, Mohamad K., et al.
Publicado: (2022)

Initial clinical evaluation of indigenous (90)Y-DOTATATE in sequential duo-PRRT approach ((177)Lu-DOTATATE and (90)Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, (90)Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects
por: Parghane, Rahul V., et al.
Publicado: (2020)

A Care Process Model to Deliver (177)Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019)

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
por: Prétot, Dominique, et al.
Publicado: (2023)

Diffuse nesidioblastosis diagnosed on a Ga-68 DOTATATE positron emission tomography/computerized tomography
por: Arun, Sasikumar, et al.
Publicado: (2013)

Ga-68 DOTATATE Positron Emission Tomography/Computed Tomography in a Rare Case of Esthesioneuroblastoma
por: Verma, Priyanka, et al.
Publicado: (2021)

Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
por: Sundlöv, Anna, et al.
Publicado: (2017)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with (177)Lu-DOTATATE
por: Strosberg, Jonathan R., et al.
Publicado: (2021)

p53-Mediated Radiosensitization of (177)Lu-DOTATATE in Neuroblastoma Tumor Spheroids
por: Lundsten, Sara, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy Using (177) Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment
por: Kalantarhormozi, Mohammadreza, et al.
Publicado: (2022)

Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE
por: Basu, Sandip, et al.
Publicado: (2016)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Corticomedullary Mixed Tumor of the Adrenal Gland with Apparent (18)F-Fluorodeoxyglucose Activity But No (68)GA-DOTATATE Uptake on Positron Emission Tomography/Computed Tomography
por: Engur, Ceren Ozge, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3d4agpn0of5p5mrpuc7as44qun